Logo image of PTGX

PROTAGONIST THERAPEUTICS INC (PTGX) Stock Price, Quote, News and Overview

NASDAQ:PTGX - Nasdaq - US74366E1029 - Common Stock - Currency: USD

44.92  -0.59 (-1.3%)

PTGX Quote, Performance and Key Statistics

PROTAGONIST THERAPEUTICS INC

NASDAQ:PTGX (5/5/2025, 9:57:56 AM)

44.92

-0.59 (-1.3%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High60.6
52 Week Low25.23
Market Cap2.78B
Shares61.96M
Float59.71M
Yearly DividendN/A
Dividend YieldN/A
PE10.7
Fwd PEN/A
Earnings (Next)05-05 2025-05-05/amc
IPO08-11 2016-08-11


PTGX short term performance overview.The bars show the price performance of PTGX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15 20

PTGX long term performance overview.The bars show the price performance of PTGX in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of PTGX is 44.92 USD. In the past month the price decreased by -2.13%. In the past year, price increased by 74.43%.

PROTAGONIST THERAPEUTICS INC / PTGX Daily stock chart

PTGX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.13 347.60B
AMGN AMGEN INC 13.3 148.46B
VRTX VERTEX PHARMACEUTICALS INC 1726.41 128.71B
GILD GILEAD SCIENCES INC 13.29 128.03B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 344.63 39.98B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.01B
ONC BEIGENE LTD-ADR N/A 27.06B
BNTX BIONTECH SE-ADR N/A 24.25B
NTRA NATERA INC N/A 21.28B
SMMT SUMMIT THERAPEUTICS INC N/A 20.14B
BIIB BIOGEN INC 7.73 17.91B

About PTGX

Company Profile

PTGX logo image Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 126 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Company Info

PROTAGONIST THERAPEUTICS INC

7707 Gateway Blvd Ste 140

Newark California CALIFORNIA 94560 US

CEO: Dinesh V. Patel

Employees: 126

PTGX Company Website

PTGX Investor Relations

Phone: 15104740170

PROTAGONIST THERAPEUTICS INC / PTGX FAQ

What is the stock price of PROTAGONIST THERAPEUTICS INC today?

The current stock price of PTGX is 44.92 USD. The price decreased by -1.3% in the last trading session.


What is the ticker symbol for PROTAGONIST THERAPEUTICS INC stock?

The exchange symbol of PROTAGONIST THERAPEUTICS INC is PTGX and it is listed on the Nasdaq exchange.


On which exchange is PTGX stock listed?

PTGX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PROTAGONIST THERAPEUTICS INC stock?

16 analysts have analysed PTGX and the average price target is 70.83 USD. This implies a price increase of 57.69% is expected in the next year compared to the current price of 44.92. Check the PROTAGONIST THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PROTAGONIST THERAPEUTICS INC worth?

PROTAGONIST THERAPEUTICS INC (PTGX) has a market capitalization of 2.78B USD. This makes PTGX a Mid Cap stock.


How many employees does PROTAGONIST THERAPEUTICS INC have?

PROTAGONIST THERAPEUTICS INC (PTGX) currently has 126 employees.


What are the support and resistance levels for PROTAGONIST THERAPEUTICS INC (PTGX) stock?

PROTAGONIST THERAPEUTICS INC (PTGX) has a support level at 45.35 and a resistance level at 45.66. Check the full technical report for a detailed analysis of PTGX support and resistance levels.


Is PROTAGONIST THERAPEUTICS INC (PTGX) expected to grow?

The Revenue of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -69.2% in the next year. Check the estimates tab for more information on the PTGX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PROTAGONIST THERAPEUTICS INC (PTGX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PROTAGONIST THERAPEUTICS INC (PTGX) stock pay dividends?

PTGX does not pay a dividend.


When does PROTAGONIST THERAPEUTICS INC (PTGX) report earnings?

PROTAGONIST THERAPEUTICS INC (PTGX) will report earnings on 2025-05-05, after the market close.


What is the Price/Earnings (PE) ratio of PROTAGONIST THERAPEUTICS INC (PTGX)?

The PE ratio for PROTAGONIST THERAPEUTICS INC (PTGX) is 10.7. This is based on the reported non-GAAP earnings per share of 4.2 and the current share price of 44.92 USD. Check the full fundamental report for a full analysis of the valuation metrics for PTGX.


What is the Short Interest ratio of PROTAGONIST THERAPEUTICS INC (PTGX) stock?

The outstanding short interest for PROTAGONIST THERAPEUTICS INC (PTGX) is 9.42% of its float. Check the ownership tab for more information on the PTGX short interest.


PTGX Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to PTGX. When comparing the yearly performance of all stocks, PTGX is one of the better performing stocks in the market, outperforming 96.11% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PTGX Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PTGX. PTGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PTGX Financial Highlights

Over the last trailing twelve months PTGX reported a non-GAAP Earnings per Share(EPS) of 4.2. The EPS increased by 381.88% compared to the year before.


Industry RankSector Rank
PM (TTM) 63.34%
ROA 36.95%
ROE 40.75%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%350%
Sales Q2Q%184.4%
EPS 1Y (TTM)381.88%
Revenue 1Y (TTM)624.05%

PTGX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to PTGX. The Buy consensus is the average rating of analysts ratings from 16 analysts.

For the next year, analysts expect an EPS growth of -142.81% and a revenue growth -69.2% for PTGX


Ownership
Inst Owners106.3%
Ins Owners1.46%
Short Float %9.42%
Short Ratio4.15
Analysts
Analysts83.75
Price Target70.83 (57.68%)
EPS Next Y-142.81%
Revenue Next Year-69.2%